Evidence map›Paper›PMID 29510325›Full record

ArticleMultiple sclerosis and related disorders2018

Could antiretrovirals be treating EBV in MS? A case report.

Natalia C Drosu, Elazer R Edelman, David E Housman

Open access · hybridAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Multiple sclerosis and related disorders, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Natalia C DrosuDepartment of Biology, Massachusetts Institute of Technology, Cambridge, MA, United States; Health Sciences & Technology, Harvard Medical School, Boston, MA, United States. Electronic address: ncd@mit.edu.
Elazer R EdelmanHealth Sciences & Technology, Harvard Medical School, Boston, MA, United States; Institute for Medical Engineering & Science, Massachusetts Institute of Technology, Cambridge, MA, United States; Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, United States. Electronic address: ere@mit.edu.
David E HousmanDepartment of Biology, Massachusetts Institute of Technology, Cambridge, MA, United States. Electronic address: dhousman@mit.edu.
Harvard University · USMassachusetts Institute of Technology · US

Funding

PRE-DOCTORAL TRAINING IN THE BIOLOGICAL SCIENCEST32GM007287 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI BELL, STEPHEN P., KEATING, AMY E · 1985 to 2019
$40.8M
Vascular Drug Delivery - Supplement for EquipmentR01GM049039 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI EDELMAN, ELAZER R · 1994 to 2019
$8.9M
NIGMS NIH HHS R01 GM049039NIGMS NIH HHS T32 GM007287
6 · The paper itself

Abstract

We present the case of an HIV-negative patient clinically diagnosed with relapsing-remitting MS who achieved significant disease improvement on Combivir (zidovudine/lamivudine). Within months of treatment, the patient reported complete resolution of previously unremitting fatigue and paresthesiae, with simultaneous improvements in lesion burden detected by MRI. All improvements have been sustained for more than three years. This response may be related to the action of zidovudine as a known inhibitor of EBV lytic DNA replication, suggesting future directions for clinical investigation.

Indexed as

AdultBrainDrug CombinationsEpstein-Barr Virus InfectionsFatigueFemaleHumansImmunologic FactorsLamivudineMultiple Sclerosis, Relapsing-RemittingReverse Transcriptase InhibitorsZidovudineDrug CombinationsImmunologic FactorsLamivudinelamivudine, zidovudine drug combinationReverse Transcriptase InhibitorsZidovudineEpstein-Barr virusMultiple sclerosis

Identifiers

PMID29510325
PMCPMC6100748
OpenAlexW2788815279

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.